Clinical Pharmacokinetics and Pharmacodynamics of Safinamide

Pregabalin for the Treatment of Restless Legs Syndrome

(2016) Emily Griffin et al.   ANNALS OF PHARMACOTHERAPY

Safinamide: First Global Approval

(2015) Emma D. Deeks   DRUGS

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

(2015) Rajesh Pahwa et al.   MOVEMENT DISORDERS

Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease

(2015) Mona Sadeghian et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease

(2014) Rupam Borgohain et al.   MOVEMENT DISORDERS

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

(2014) Robert A. Hauser et al.   MOVEMENT DISORDERS

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity

(2013) Jasmin Bartl et al.   JOURNAL OF NEURAL TRANSMISSION

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

(2013) Rupam Borgohain et al.   MOVEMENT DISORDERS

Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys

(2013) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers

(2013) Chiara Leuratti et al.   PHARMACOLOGY

Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor

(2013) Samantha Podurgiel et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

(2013) Kay Teo et al.   Translational Neurodegeneration

Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects

(2012) Sonja Krösser et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Rasagiline

(2012) Sheridan M. Hoy et al.   DRUGS

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

(2012) A. H. V. Schapira et al.   EUROPEAN JOURNAL OF NEUROLOGY

Dopamine, Corticostriatal Connectivity, and Intertemporal Choice

(2012) A. S. Kayser et al.   JOURNAL OF NEUROSCIENCE

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

(2011) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers

(2011) Andrea Francesco Daniele Di Stefano et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro

(2011) W Dimpfel et al.   BMC Pharmacology & Toxicology

MAO-inhibitors in Parkinson's Disease

(2011) Peter Riederer et al.   Experimental Neurobiology

Tolcapone Effects on Gating, Working Memory, and Mood Interact with the Synonymous Catechol-O-methyltransferase rs4818C/G Polymorphism

(2009) Panos Roussos et al.   BIOLOGICAL PSYCHIATRY

NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease

(2009) Sara Varanese et al.   MOVEMENT DISORDERS

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

(2009) Paolo Barone et al.   MOVEMENT DISORDERS

What do clinical trials tell us about treating patients?

(2009) William J. Weiner   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells

(2008) Thomas Müller et al.   NEUROLOGICAL RESEARCH